Objective: To evaluate outcomes following loss of primary patency (LPP) in superficial femoral (SFA) and popliteal (Pop) arteries treated by endovascular intervention (EVI) Methods: The medical records of all SFA/Pop EVI performed by 2 Vascular Surgeons between 2005-2008 were reviewed to identify LPP defined as occlusion or need for re-intervention documented by duplex or angiography. TASC II, EVI type, Rutherford Score (RS) and Rutherford Improvement Scores (RIS) were recorded. Analysis was completed with SPSS 15.
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Contemporary Results with Endovascular Therapy for Acute Limb Ischemia
Ramyar Gilani, Mohsen Bannazadeh, James F Bena, Timur P Sarac, Vikram S Kashyap. The Cleveland Clinic Foundation, Cleveland, OH Objective: Endovascular therapies play an increasing role in the treatment of acute limb ischemia. The purpose of this study was to assess outcomes in patients treated for acute limb ischemia (ALI) with intra-arterial thrombolysis and/or percutaneous mechanical thrombectomy (PMT).
Methods: Consecutive patients (nϭ 76) with ALI of the lower extremities treated via intra-arterial methods between January 1, 2005 and December 31, 2006 were identified and reviewed. Overall estimates of patency, limb salvage, and survival at 1 and 2 years were made using Kaplan-Meier estimation. Hazard ratios from Cox proportional hazards models were used to estimate differences in risk between groups for patency and survival.
Results: Patients with ALI (82 limbs) presenting with native artery or graft thrombosis (76%) underwent thrombolysis and PMT (46%) under local anesthesia (96%) for an average of 1.6 days. Adjunctive procedures were required in 94% of patients to treat the culprit lesion with solely open revascularization in 16%. One patient had a major bleeding episode, but there was no intracranial hemorrhage in this cohort. 30-day amputation and mortality rates were 14% and 6%. Primary patency at 1 and 2 years were 52.1% (95% CI, 39.3-64.8), and 41.6% (95% CI, 27.9-55.4), while secondary patency rates at 1 and 2 years were 74.6% (95% CI, 63.7-85.5), and 67.5% (95% CI, 55.1-80.0) respectively (median follow upϭ22.5 months). Limb salvage at 1 and 2 years was 86.5% (95% CI, 77.7-95.3) and 81.9% (95% CI, 71.5-92.3). Patients on dialysis (HR, 3.82; 95% CI, 2.22-6.59; PϽ0.001) and elevated creatinine levels (HR 1.16; 95% CI, 1.05-1.29; Pϭ0.004) were associated with primary patency loss. Overall survival at 1 and 2 years was 83.4% (95% CI, 74.4-92.4) and 81.6% (95% CI, 72.1-91.1). Women were at an increased risk for mortality (HR, 16.93 Methods: Thirteen males and fourteen females, mean age 73Ϯ11 years underwent 28 VASIR for severe (TASC C 8/28, TASC D 20/28; 4/28 no continuous infrapopliteal run-off artery) SFA disease. Indications were claudication (14/28 limbs), ischemic rest pain (6/28), and tissue loss (8/28). VASIR was chosen instead of bypass due to comorbidities or lack of vein. Patients received aspirin and, if not already taking warfarin, they also received clopidogrel. Patients were examined with ABI and duplex scan at 1 month, then every 3 months after VASIR.
Results VASIR was technically successful in all. ABI averaged .47Ϯ.17 pre-procedure, .89Ϯ.20 post-procedure, and increased by .15 or more in every case. Median follow-up is 20 months. There were 3 perioperative (Ͻ30 days) and 7 later failures including revision prior to any thrombosis. One patient required amputation. Four have died, two with patent grafts, none from causes related to VASIR, all more than 30 days post-VASIR. Estimated one year primary and secondary patency were 70Ϯ11% and 73Ϯ10%. Failure was not significantly associated with indications, comorbidities, or runoff status. There was a clear distinction between patients with early failure and the rest of the patients. None of 8 patients with failure in the first 8 months after surgery has a patent graft. However, of 17 grafts primarily patent at 8 months, only two have failed (one thrombosed, one required preemptive balloon angioplasty). Furthermore, although warfarin was not prescribed as part of the protocol, no patient taking warfarin before and who resumed warfarin after VASIR (nϭ4) suffered failure.
Conclusions: Despite significant early failures, we found VASIR to be durable in those who did not suffer early failure. VASIR is an acceptable alternative to vein bypass in selected patients with severe SFA disease. Warfarin may be valuable to reduce the risk of failure after VASIR.
